The U.S. Chamber submitted comments to the European Commission as it considers revisions and updates to its General Pharmaceuticals Legislation, which is Europe’s attempt to foster innovation, improve the resiliency of the healthcare sector in Europe, bolster supply chain security, and ensure access to innovative medicines across the EU. We encouraged the EU to do a better job of rewarding and prioritizing innovation, guarantee strong IP protections for manufacturers, and preserve open and integrated global supply chains rather than attempting to cut Europe off from the global economy in healthcare. We also focused on the importance of digital health and transatlantic coordination, including for research and pandemic response and recovery.
Recommended
- International
13th U.S.-Mexico CEO Dialogue: Everything You Need to Know
The U.S.-Mexico CEO Dialogue is taking place Sept. 27-28, 2023. Read more about the exclusive forum that focuses on investment and the bilateral trade relationship between the U.S. and Mexico.
By Megan Bridges
- International
An Investment Agenda for the Indo-Pacific
By Isabelle Icso
- International
U.S. Chamber at UNGA: Turning Ambition into Action
By Anthony Hahn - International
A Year on the Road with “Advance with Africa”
By Ellington Arnold
View this online